Many drugmakers rang in the new year with increases in list prices of dozens of drugs that will take effect in 2018.
Many drugmakers rang in the new year with increases in list prices of dozens of drugs that will take effect in 2018. Early data suggest the increases generally remained within a 10% self-imposed limit that was popularized by Allergan’s chief executive, Brent Saunders, in 2016, when he pledged to keep price rises below the 10% figure as part of what he called the company’s “social contract with patients.”
Saunders’ pricing promise may have become something of a de facto price pledge for many companies, one that was made in response to Mylan’s price hike on Epipen auto-injectors, which set off a public controversy. Pfizer has been a notable exception to the voluntary 10% price cap pledge. In 2017, Pfizer raised US prices on close to 100 of its drugs by an average of 20%.
Amgen raised the price of its reference etanercept (Enbrel), its blockbuster rheumatoid arthritis and psoriasis treatment, by 9.7%, and also raised the price of its pegfilgrastim (Neulasta) by 4.9%. An FDA approved biosimilar etanercept, Erelzi, has not yet launched in the United States.
Specialty pharma companies Allergan, Teva, Collectis, Insys, Synergy, and Supernus all raised prices effective January 1. Allergan raised prices on 18 different medications by 9.5%—just below its self-imposed limit—including its hypertension treatment Bystolic, dry eye treatment Restasis (which was the subject of considerable controversy in 2017), irritable bowel syndrome treatment Linzess, and Alzheimer’s treatment Namenda XR. An Allergan company spokesman said that these increases will be the only ones taken on those brands in 2018, and he noted that discounts to payers should bring actual increases to consumers down to the low single digits—approximately 2% to 3%.
Teva increased prices on 7 of its drugs, focusing on its branded products including Azilect, its Parkinson’s treatment, and the ProAir HFA and ProAir RespiClick asthma inhalers, which went up by 6% and 3%, respectively. Teva’s price increases overall range from 2.3% to 9.4%. The price hikes come as Teva has publicized plans to lay off 14,000 of its employees, setting off social unrest in Israel, where the layoffs will hit particularly hard.
The biopharmaceutical company Horizon Pharma kept price hikes on 4 of its drugs at 9.9%.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.